M-chat-r Screening
M-chat-r Screening - Related Videos
12:28
Bacterial Inner-membrane Display for Screening a Library of Antibody Fragments
0 Views •
Cited by 8 •
2016
We provide a method to simultaneously screen a library of antibody fragments for binding affinity and cytoplasmic solubility by using the Escherichia coli twin-arginine translocation pathway, which has an inherent quality control mechanism for intracellular protein folding, to display the antibody fragments on the inner membrane.
09:40
RNAi Screening to Identify Postembryonic Phenotypes in C. elegans
0 Views •
Cited by 9 •
2012
We describe a sensitized method to identify postembryonic regulators of protein expression and localization in C. elegans using an RNAi-based genomic screen and an integrated transgene that expresses a functional, fluorescently tagged protein.
09:44
High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
0 Views •
2015
Here we describe a cell-based reporter gene assay as a valuable tool to screen chemical libraries for compounds modulating post-transcriptional control mechanisms exerted through 3’ UTR.
08:50
Genetic Screens
0 Views •
2023
Genetic screens are critical tools for defining gene function and understanding gene interactions. Screens typically involve mutating genes and then assessing the affected organisms for phenotypes of interest. The process can be “forward”, where mutations are generated randomly to identify unknown genes responsible for the phenotypes, or it can be “reverse”, where specific genes are targeted for mutation to observe what phenotypes are produced.Here, JoVE reviews various types of genetic...
08:10
Multi-enzyme Screening Using a High-throughput Genetic Enzyme Screening System
0 Views •
Cited by 7 •
2016
This work presents a method of high-throughput screening using a universal genetic enzyme screening system that can be theoretically applied to over 200 enzymes. Here, the single screening system identifies three different enzymes (lipase, cellulase, and alkaline phosphatase) by simply changing the substrate used (p-nitrophenyl acetate, p-nitrophenyl-β-D-cellobioside, and phenyl phosphate).
FAQs
The 20 yes-or-no items focus on early social communication and behavior, allowing parent observations to be organized into a consistent screening result. Responses indicating an elevated likelihood do not establish autism spectrum disorder; instead, they signal that the child may benefit from closer developmental evaluation. This makes the tool useful for recognizing concerns that warrant professional attention.
The follow-up interview provides a planned opportunity to examine responses that suggest elevated likelihood and to place them in a clearer clinical context. Rather than treating an initial pattern of answers as conclusive, healthcare professionals use this additional step before guiding families toward developmental assessment or other appropriate services. It therefore supports more informed referral decisions.
Screening estimates whether a child may warrant further evaluation, whereas diagnosis requires a broader developmental assessment by qualified professionals. M-CHAT-R screening contributes information from parent-reported social communication and behavioral observations, but it cannot confirm or rule out autism spectrum disorder by itself. Its clinical value lies in guiding the next step, not replacing diagnostic evaluation.
An elevated screening result can prompt healthcare professionals to recommend further developmental evaluation. That process may help clarify the child’s developmental profile and determine whether diagnostic or support services are appropriate. In clinical practice, the screening result functions as a referral guide, helping families connect with assessment and early-intervention resources rather than providing a final clinical conclusion.
Parents provide the observations used to answer the screening questions, particularly information about the child’s early social communication and behavior. Their responses supply an important perspective for the healthcare professional reviewing the result. Clinicians then use that information, including any need for structured follow-up, to decide whether developmental assessment or additional services should be considered.
The tool is designed for children between 16 and 30 months, so its intended clinical use is tied to that developmental age range. Applying it within this range helps healthcare professionals use the screening approach with the population for which it was designed. Results should still be treated as indicators for possible follow-up, not as a diagnosis.